The proposed study is a multi-institutional historical chart review and longitudinal follow-up of identified patients with Wolman disease (WD) or Cholesteryl Ester Storage disease (CESD), lysosomal acid lipase deficiency (LAL). The overall goal of the proposed studies is to document and characterize the phenotypes, and their progression, as well as the determination of the genotypes of patients with lysosomal acid lipase (LAL;LPA locus) defects in the severe (WD) and attenuated (CESD) variants.
The specific aims are: 1. To characterize the degrees and progression of hepatic, splenic, intestinal, lung and adrenal involvement in CESD and WD using quantitative clinical assessments and to correlate these abnormalities with the genotype at the LPA locus. 2. To determine the variability of the phenotype in WD, a lethal infantile disease, and to quantify the rate of change of hepatic, splenic, intestinal malabsorptive and adrenal defects. These will be correlated with the genotype at the LPA locus. 3. Verify the impression that CSED and WD are non-CNS diseases and that CESD is significantly under diagnosed due to its marked variability with severely ill infants and nearly normal adults with """"""""fatty livers."""""""" Correlations with mutation, biopsy (e.g.,liver), and serum cholesterol and triglyceride levels will be developed as historical controls for future ERT trials.
Wolman disease or Cholesteryl Ester Storage (CESD) disease patients will be studied to determine the natural history of liver, spleen, intestinal, lung and adrenal involvement, the relationship to their genotype, to verify that these diseases do not affect the central nervous system and to determine if CESD is underdiagnosed. This data will be essential for comparison for future enzyme replacement.
|Schneider, Joseph; Burmeister, Lynn A; Rudser, Kyle et al. (2016) Hypothyroidism in late-onset Pompe disease. Mol Genet Metab Rep 8:24-7|
|Polgreen, Lynda E; Vehe, Richard K; Rudser, Kyle et al. (2016) Elevated TNF-Î± is associated with pain and physical disability in mucopolysaccharidosis types I, II, and VI. Mol Genet Metab 117:427-30|
|Shapiro, Elsa G; Rudser, Kyle; Ahmed, Alia et al. (2016) A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II. Mol Genet Metab Rep 7:32-9|
|Dyke, J P; Sondhi, D; Voss, H U et al. (2016) Brain Region-Specific Degeneration with Disease Progression in Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease). AJNR Am J Neuroradiol 37:1160-9|
|Najafian, Behzad; TÃ¸ndel, Camilla; Svarstad, Einar et al. (2016) One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease. PLoS One 11:e0152812|
|Shapiro, E; King, K; Ahmed, A et al. (2016) The Neurobehavioral Phenotype in Mucopolysaccharidosis Type IIIB: an Exploratory Study. Mol Genet Metab Rep 6:41-47|
|Rappaport, Jeff; Manthe, Rachel L; Solomon, Melani et al. (2016) A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders. Mol Pharm 13:357-68|
|Ahmed, Alia; Shapiro, Elsa; Rudser, Kyle et al. (2016) Association of somatic burden of disease with age and neuropsychological measures in attenuated mucopolysaccharidosis types I, II and VI. Mol Genet Metab Rep 7:27-31|
|Karimian, Zahra; Whitley, Chester B; Rudser, Kyle D et al. (2016) Delayed Infusion Reactions to Enzyme Replacement Therapies. JIMD Rep :|
|Kazi, Zoheb B; Prater, Sean N; Kobori, Joyce A et al. (2016) Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses. JCI Insight 1:|
Showing the most recent 10 out of 84 publications